Cardiovascular Diabetology

Article	Citations
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin	323
Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations	279
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin	213
Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies	189
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)	138
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort	134
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs	131
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management	131
Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis	128
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries	122
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction	115
Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort	107
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis	107
Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-centre study	105
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study	104
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease	100
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry	100
Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study	97
Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications	90
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analy	86
Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up	84
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study	84
Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system	82
Direct cardiac effects of SGLT2 inhibitors	80
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs	80

Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population	79
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins	76
Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study	75
Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data	74
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management	74
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes	74
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA	74
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte	72
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy	69
Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents	69
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs	68
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF	67
Association between the triglyceride–glucose index and severity of coronary artery disease	65
Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure	65
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention	64
The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018	64
Variability of risk factors and diabetes complications	62
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis	61
MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics	61
TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients	59
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus	59
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug	59
Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis	57
Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications	57
Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study	57
Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus	56
Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study	56
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk	54
Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study	53
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling	53
The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis	53
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA	52
Predictive effect of triglyceride‑glucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China	52
Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study	51
Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report	51
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors	50
Diabetes and restenosis	50
Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: a nationwide population-based cohort study	50
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis	50
Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China	48
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect	48
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 tr	48
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis	48
Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis	48
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study	47
Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults	47
Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study	47
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death	47
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study	47
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial	47

Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary	46
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management	46
Triglyceride-glucose index and common carotid artery intima-media thickness in patients with ischemic stroke	46
The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction	46
Triglyceride-glucose index and heart failure: a systematic review and meta-analysis	44
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis	43
Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database	43
Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study	43
Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes	43
Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study	43
Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus	43
Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study	43
Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients	42
Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults	42
The association of hepatic steatosis and fibrosis with heart failure and mortality	41
Association between the Mediterranean lifestyle, metabolic syndrome and mortality: a whole-country cohort in Spain	41
Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study	41
Relationship of cumulative exposure to the triglyceride-glucose index with ischemic stroke: a 9-year prospective study in the Kailuan cohort	40
Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study	40
The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018	40
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression	39
MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes	39
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus	38
Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway	37
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the	37
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis	37
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)	37
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system	37
Comparison of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus	36
HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target	36
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach	36
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND	35
High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort	35
Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study	35
The triglyceride-glucose index predicts ischemic heart disease risk in Koreans: a prospective study using National Health Insurance Service data	35
Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial	35
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study	34
Insulin directly stimulates mitochondrial glucose oxidation in the heart	34
Landscape of cardiometabolic risk factors in Chinese population: a narrative review	34
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence	34
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease	34
Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients	34
Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes	34
Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) Study	33
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system	33
Triglyceride-glucose index trajectory and arterial stiffness: results from Hanzhong Adolescent Hypertension Cohort Study	33
Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome	33
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure	33
Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China	32
High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study	32
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney	32
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis	32
Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study	31
Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance	31
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes	31
Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study	31
Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study	31
Association between physical activity level and cardiovascular risk factors in adolescents living with type 1 diabetes mellitus: a cross-sectional study	31
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events	31
Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study	31
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats	31
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes	31
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis	31
Association between triglyceride-glucose index and all-cause mortality in critically ill patients with ischemic stroke: analysis of the MIMIC-IV database	30
Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension	30
Association between triglyceride glucose index and risk of cerebrovascular disease: systematic review and meta-analysis	30
High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: a large-scale cohort study	30
Association of visceral adiposity index with incident nephropathy and retinopathy: a cohort study in the diabetic population	30
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort stu	30
Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study	29
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms	29
Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry	29
Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project	29
Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China	29
Cardiovascular complications in a diabetes prediction model using machine learning: a systematic review	29
Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium	29
Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes	29
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial	28
Sex differences in the association of prediabetes and type 2 diabetes with microvascular complications and function: The Maastricht Study	28
Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study	28

High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort st	28
Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort	28
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes	28
Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects	28
Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review	28
Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease: insights from a large cohort study	28
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases	27
Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease	27
Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus	27
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention	27
Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus	27
Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction	27
Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study	27
Prognostic significance of diabetes mellitus in patients with atrial fibrillation	27
Sex-specific differences in the effect of the atherogenic index of plasma on prediabetes and diabetes in the NHANES 2011–2018 population	27
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes	27
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial	27
Impact of red cell distribution width and red cell distribution width/albumin ratio on all-cause mortality in patients with type 2 diabetes and foot ulcers: a retrospective cohort study	27
Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study	27
Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics	26
Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis	26
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors	26
Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study	26
Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study	26
Association between healthy lifestyle and the occurrence of cardiometabolic multimorbidity in hypertensive patients: a prospective cohort study of UK Biobank	26
A molecular signature for the metabolic syndrome by urine metabolomics	25
Association between triglyceride-glucose index and carotid atherosclerosis detected by ultrasonography	25
Associations between the triglyceride-glucose index and cardiovascular disease in over 150,000 cancer survivors: a population-based cohort study	25
Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient	25
Association of triglyceride glucose index with all-cause and cardiovascular mortality in the general population	25
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy	25
Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes	25
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial	25
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation	25
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EURO	24
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off	24
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐contro	24
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure	24
The neutrophil–lymphocyte ratio as a risk factor for all-cause and cardiovascular mortality among individuals with diabetes: evidence from the NHANES 2003–2016	24
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio	24
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report	24
Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study	23
Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications	23
Positive association of triglyceride-glucose index with new-onset hypertension among adults: a national cohort study in China	23
Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling	23
Importance of hematological parameters for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study	23
Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study	23
Gender differences in changes in metabolic syndrome status and its components and risk of cardiovascular disease: a longitudinal cohort study	23
Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis	23
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program	22
Metabolic syndrome and the plasma proteome: from association to causation	22
Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study	22
Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation	22
Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study	22
Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease	22
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)	22
Triglyceride glucose index combined with plaque characteristics as a novel biomarker for cardiovascular outcomes after percutaneous coronary intervention in ST-elevated myocardial infarction patients:	22
The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy	22
Changes in the triglyceride glucose-body mass index estimate the risk of stroke in middle-aged and older Chinese adults: a nationwide prospective cohort study	22
The cardio-renal-metabolic connection: a review of the evidence	22
Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes	22
Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit	22
Angiogenic content of microparticles in patients with diabetes and coronary artery disease predicts networks of endothelial dysfunction	22
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4	21
Epicardial adipose tissue volume and coronary calcification among people living with diabetes: a cross-sectional study	21
Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus	21
The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone	21
Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults	21
Diabetes and other vascular risk factors in association with the risk of lower extremity amputation in chronic limb-threatening ischemia: a prospective cohort study	21
Triglycerides/HDL cholesterol ratio and type 2 diabetes incidence: Panasonic Cohort Study 10	21
Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study	21
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review	21
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLE	21
L-Arginine in diabetes: clinical and preclinical evidence	21
The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes: a 16-year cohort study	20
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness	20
Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention	20
Short and long-term prognosis of admission hyperglycemia in patients with and without diabetes after acute myocardial infarction: a retrospective cohort study	20
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease	20
Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study	20
The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia	20
Prognostic value of coronary microvascular dysfunction assessed by coronary angiography-derived index of microcirculatory resistance in diabetic patients with chronic coronary syndrome	20
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials	20
Association between the triglyceride glucose (TyG) index and the risk of acute kidney injury in critically ill patients with heart failure: analysis of the MIMIC-IV database	20
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes	19
Traditional and non-traditional risk factors for peripheral artery disease development/progression in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study	19
Long-term cardiovascular outcomes of gestational diabetes mellitus: a prospective UK Biobank study	19
Associations of continuous glucose monitoring-assessed glucose variability with intima-media thickness and ultrasonic tissue characteristics of the carotid arteries: a cross-sectional analysis in pati	19
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials	19
Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study	19
Association between triglyceride glucose index and atherosclerotic plaques and Burden: findings from a community-based study	19
Cardiovascular and metabolic morbidity in women with previous gestational diabetes mellitus: a nationwide register-based cohort study	19
Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance	19
Predicting long-term prognosis after percutaneous coronary intervention in patients with new onset ST-elevation myocardial infarction: development and external validation of a nomogram model	19
Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension	19